Taysha Gene Therapies Stock Investor Sentiment

TSHA Stock  USD 1.52  0.01  0.65%   
About 61% of Taysha Gene's investor base is looking to short. The analysis of the overall investor sentiment regarding Taysha Gene Therapies suggests that many traders are alarmed. The current market sentiment, together with Taysha Gene's historical and current headlines, can help investors time the market. In addition, many technical investors use Taysha Gene Therapies stock news signals to limit their universe of possible portfolio assets.
  

Taysha Gene Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Taysha Gene can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at finance.yahoo.com         
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy Designation Granted by U.S. F...
Yahoo News
over six months ago at zacks.com         
Will Taysha Gene Therapies, Inc. Report Negative Q1 Earnings What You Should Know
zacks News
over six months ago at news.google.com         
11 Analysts Assess Taysha Gene Therapies What You Need To Know - Taysha Gene Therapies - Benzinga
Google News at Macroaxis
over six months ago at news.google.com         
The Independent Director of Taysha Gene Therapies, Inc. , Paul Manning, Just Bought A Few More ... -...
Google News at Macroaxis
over six months ago at news.google.com         
Taysha Gene Therapies Insiders Added US3.0m Of Stock To Their Holdings - Yahoo News Canada
Google News at Macroaxis
over six months ago at finance.yahoo.com         
Analysts Revenue Estimates For Taysha Gene Therapies, Inc. Are Surging Higher
Yahoo News
over six months ago at simplywall.st         
Growth Investors Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. Revenue Forecasts...
Simply Wall St News at Macroaxis
over six months ago at www.macroaxis.com         
Acquisition by Manning Paul B of 16466667 shares of Taysha Gene at 0.9 subject to Rule 16b-3
Macroaxis News
over six months ago at globenewswire.com         
Dialing Up Nights Out Heineken Bodega Launch the No-Frills Boring Phone
Macroaxis News: globenewswire.com
over six months ago at news.google.com         
Vanguard Group Inc. Purchases 3738616 Shares of Taysha Gene Therapies, Inc. - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
Taysha Gene Therapies Shares Down 7.5 percent - Defense World
Google News at Macroaxis
over six months ago at seekingalpha.com         
Taysha stock wins bullish view at Piper Sandler
seekingalpha News
over six months ago at investing.com         
Piper Sandler sets new target on Taysha Gene Therapies stock
Investing News at Macroaxis
over six months ago at news.google.com         
China Universal Asset Management Co. Ltd. Invests 38000 in Taysha Gene Therapies, Inc. - Defense Wor...
Google News at Macroaxis
over six months ago at www.macroaxis.com         
Acquisition by Prasad Suyash of 40325 shares of Taysha Gene subject to Rule 16b-3
Macroaxis News
Far too much social signal, news, headlines, and media speculation about Taysha Gene that are available to investors today. That information is available publicly through Taysha media outlets and privately through word of mouth or via Taysha internal channels. However, regardless of the origin, that massive amount of Taysha data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Taysha Gene news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Taysha Gene relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Taysha Gene's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Taysha Gene alpha.

Taysha Gene Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/13/2024
2
Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursdays Pre-Market Session
11/14/2024
3
Taysha Gene Therapies Third Quarter 2024 Earnings Revenues Beat Expectations, EPS Lags
11/15/2024
4
Taysha Gene Therapies Trading Up 13.8 percent - Heres What Happened - MarketBeat
11/22/2024
5
Taysha Gene Therapies SWOT analysis stock poised for growth in Rett syndrome market
11/26/2024
6
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635
12/06/2024
7
Fmr LLC Has 37.54 Million Stake in Taysha Gene Therapies, Inc. - MarketBeat
12/09/2024
8
Acquisition by Alam Kamran of 149900 shares of Taysha Gene at 1.18 subject to Rule 16b-3
12/13/2024
9
Why Did Taysha Gene Therapies Stock Drop Below Its Moving Average
12/20/2024
10
Acquisition by Alam Kamran of 431000 shares of Taysha Gene at 1.85 subject to Rule 16b-3
01/02/2025

Complementary Tools for Taysha Stock analysis

When running Taysha Gene's price analysis, check to measure Taysha Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Taysha Gene is operating at the current time. Most of Taysha Gene's value examination focuses on studying past and present price action to predict the probability of Taysha Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Taysha Gene's price. Additionally, you may evaluate how the addition of Taysha Gene to your portfolios can decrease your overall portfolio volatility.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk